Sarepta price target lowered to $179 from $210 at BofA

1 day ago 1

Unlock banal picks and a broker-level newsfeed that powers Wall Street.

TipRanks

Tue, Apr 1, 2025, 12:40 PM 1 min read

In This Article:

BofA lowered the firm’s price target connected Sarepta (SRPT) to $179 from $210 and keeps a Buy standing connected the shares. Following the quality of the departure of Peter Marks from the FDA’s Center for Biologics Evaluation and Research, the steadfast is lowering its Elevidys estimates by astir 20% retired of an abundance of caution. While it is early, and its speech with Sarepta contiguous indicates they don’t expect an contiguous impact, BofA thinks the unfastened spot introduces further uncertainty successful summation to the caller information update past week. Recall, Sarepta has accelerated support successful non-ambulatory patients. The steadfast has ever assumed much usage successful younger patients, but it present besides assumes little income from non-ambulatory patients. BofA present models $3.5B successful Elevidys highest sales, down from the erstwhile $4.3B. Sarepta remains a apical prime successful 2025, the steadfast adds.

Discover the latest stocks recommended by apical Wall Street analysts, each successful 1 spot with Analyst Top Stocks.
Make smarter investments with play adept banal picks from the Smart Investor Newsletter.

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See Insiders’ Hot Stocks connected TipRanks >>

Read More connected SRPT:

Disclaimer & DisclosureReport an Issue

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
Biotech stocks descent arsenic Marks resignation seen being antagonistic for sector
Okta initiated, Wingstop upgraded: Wall Street’s apical expert calls
Marks resignation ‘not good’ for biotech sector, says RBC
Vaccine, cistron therapy makers autumn aft Peter Marks resignation

Read Entire Article